{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Protease Inhibitors after 15 Years: Report from the IAS - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"41oFdS0OAg\"><a href=\"https:\/\/themedicalxchange.com\/en\/review\/6th-ias-conference-on-hiv-pathogenesis-treatment-a\/\">Protease Inhibitors after 15 Years: Report from the IAS<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/review\/6th-ias-conference-on-hiv-pathogenesis-treatment-a\/embed\/#?secret=41oFdS0OAg\" width=\"600\" height=\"338\" title=\"&#8220;Protease Inhibitors after 15 Years: Report from the IAS&#8221; &#8212; The Medical Xchange\" data-secret=\"41oFdS0OAg\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2011\/07\/IAS_XR_slides_Figure_1.png","thumbnail_width":3300,"thumbnail_height":2289,"description":"Rome - In 1996, a protease inhibitor (PI)-based antiretroviral combination led to the first opportunity for long-term survival for most patients living with human immunodeficiency virus (HIV). On the 15th anniversary of that breakthrough, PIs are no longer a mandatory component of an effective antiretroviral regimen, but they remain an important and reliable option in HIV control. As they are among the most potent antiretroviral agents, PIs remain a reasonable choice in a wide variety of clinical scenarios, including first-line treatment. Although some of the initially introduced PIs remain available, the common PIs in most formularies are ritonavir-boosted atazanavir (ATV\/r), darunavir (DRV\/r), and lopinavir (LPV\/r). Relative to first generation PIs, these have few dosing restrictions, a low pill burden, and less relative risk of adverse events. Despite the broad experience with all of these agents, optimal use of PIs remains a dynamic exploration of relative strengths and weaknesses, particularly in the context of an aging HIV-infected population. This update assembles key studies on PIs from the 2011 IAS meeting."}